American Society for Clinical Investigation, Journal of Clinical Investigation, 11(122), p. 3857-3859, 2012
DOI: 10.1172/jci65929
Full text: Download
The incidence of melanoma — the most aggressive form of skin cancer — is dramatically increasing, while the development of innovative therapeutic strategies continues to be challenging, especially due to a lack of knowledge about the molecular mechanisms underlying melanoma progression as well as antitumor immunity. In this issue of the JCI, Yong Lu and colleagues report a central role for Th9 cells in antitumor immunity.